Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00230204|
Recruitment Status : Unknown
Verified January 2006 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : September 30, 2005
Last Update Posted : February 16, 2006
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Procedure: Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits||Phase 1|
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (RA, UCTD, Sjogren, antiphospholipid syndrome - APS, vasculitides, SLE, polymyositis, Hashimoto, multiple sclerosis, PBC, etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity).
We will assess in our Center 100 patients with multiple sclerosis for the antibody profile of different infectious agents. Comparative assessments will be performed with normal matched subjects.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.|
|Study Start Date :||September 2005|
|Estimated Study Completion Date :||April 2006|
- Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis
- Assess correlation between antibody levels to various infectious agents with clinical disease variables
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230204
|Contact: Anat Achiron, MD, PhDfirstname.lastname@example.org|
|Contact: Yehuda Shoenfeld, MDemail@example.com|
|Multiple Sclerosis Center, Sheba Medical Center||Recruiting|
|Ramat-gan, Israel, 52621|
|Contact: Anne Levy 972-3-5303932 firstname.lastname@example.org|
|Principal Investigator: Anat Achiron, MD, PhD|
|Principal Investigator:||Anat Achiron, MD, PhD||Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel|
|Principal Investigator:||Yehuda Shoenfeld||Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel|